169 related articles for article (PubMed ID: 31010844)
21. General anaesthetics reduce acute lymphoblastic leukaemia malignancies
Jiang C; Gonzalez-Anton S; Li X; Mi E; Wu L; Zhao H; Zhang G; Lu A; Lo Celso C; Ma D
F1000Res; 2022; 11():1491. PubMed ID: 38798305
[TBL] [Abstract][Full Text] [Related]
22. Chemokines and relapses in childhood acute lymphoblastic leukemia: A role in migration and in resistance to antileukemic drugs.
Gómez AM; Martínez C; González M; Luque A; Melen GJ; Martínez J; Hortelano S; Lassaletta Á; Madero L; Ramírez M
Blood Cells Mol Dis; 2015 Oct; 55(3):220-7. PubMed ID: 26227851
[TBL] [Abstract][Full Text] [Related]
23. Development of resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment in childhood lymphoblastic leukemia: analysis of resistance mechanism in established cell lines.
Kees UR; Ford J; Dawson VM; Piall E; Aherne GW
Cancer Res; 1989 Jun; 49(11):3015-9. PubMed ID: 2720661
[TBL] [Abstract][Full Text] [Related]
24. Characterization of cytarabine-resistant leukemic cell lines established from five different blood cell lineages using gene expression and proteomic analyses.
Negoro E; Yamauchi T; Urasaki Y; Nishi R; Hori H; Ueda T
Int J Oncol; 2011 Apr; 38(4):911-9. PubMed ID: 21290089
[TBL] [Abstract][Full Text] [Related]
25. Characterization of resistance to cytosine arabinoside (Ara-C) in NALM-6 human B leukemia cells.
Kanno S; Hiura T; Ohtake T; Koiwai K; Suzuki H; Ujibe M; Ishikawa M
Clin Chim Acta; 2007 Feb; 377(1-2):144-9. PubMed ID: 17097625
[TBL] [Abstract][Full Text] [Related]
26. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy.
Sengupta TK; Leclerc GM; Hsieh-Kinser TT; Leclerc GJ; Singh I; Barredo JC
Mol Cancer; 2007 Jul; 6():46. PubMed ID: 17623090
[TBL] [Abstract][Full Text] [Related]
27. Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance.
Nowak D; Liem NL; Mossner M; Klaumünzer M; Papa RA; Nowak V; Jann JC; Akagi T; Kawamata N; Okamoto R; Thoennissen NH; Kato M; Sanada M; Hofmann WK; Ogawa S; Marshall GM; Lock RB; Koeffler HP
Exp Hematol; 2015 Jan; 43(1):32-43.e1-35. PubMed ID: 25450514
[TBL] [Abstract][Full Text] [Related]
28. [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine].
Xie XT; Jiang SY; Li BS; Yang LL
Zhonghua Er Ke Za Zhi; 2008 Apr; 46(4):276-80. PubMed ID: 19099730
[TBL] [Abstract][Full Text] [Related]
29. MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemia.
Evensen NA; Madhusoodhan PP; Meyer J; Saliba J; Chowdhury A; Araten DJ; Nersting J; Bhatla T; Vincent TL; Teachey D; Hunger SP; Yang J; Schmiegelow K; Carroll WL
Haematologica; 2018 May; 103(5):830-839. PubMed ID: 29449434
[TBL] [Abstract][Full Text] [Related]
30. The AKT/NF-κB inhibitor xanthohumol is a potent anti-lymphocytic leukemia drug overcoming chemoresistance and cell infiltration.
Benelli R; Venè R; Ciarlo M; Carlone S; Barbieri O; Ferrari N
Biochem Pharmacol; 2012 Jun; 83(12):1634-42. PubMed ID: 22445931
[TBL] [Abstract][Full Text] [Related]
31. 5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox.
Müller F; Cunningham T; Stookey S; Tai CH; Burkett S; Jailwala P; Stetler Stevenson M; Cam MC; Wayne AS; Pastan I
Proc Natl Acad Sci U S A; 2018 Feb; 115(8):E1867-E1875. PubMed ID: 29432154
[TBL] [Abstract][Full Text] [Related]
32. Autophagy Inhibition Potentiates the Anticancer Effects of a Bendamustine Derivative NL-101 in Acute T Lymphocytic Leukemia.
Gao H; Lou S; Hong H; Ge Q; Zhao H
Biomed Res Int; 2020; 2020():1520651. PubMed ID: 32149078
[TBL] [Abstract][Full Text] [Related]
33. In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.
Kano Y; Akutsu M; Tsunoda S; Suzuki K; Ichikawa A; Furukawa Y; Bai L; Kon K
Leukemia; 2000 Mar; 14(3):379-88. PubMed ID: 10720130
[TBL] [Abstract][Full Text] [Related]
34. Induction of cytosine arabinoside-resistant human myeloid leukemia cell death through autophagy regulation by hydroxychloroquine.
Kim Y; Eom JI; Jeung HK; Jang JE; Kim JS; Cheong JW; Kim YS; Min YH
Biomed Pharmacother; 2015 Jul; 73():87-96. PubMed ID: 26211587
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapeutic Activity of Pitavastatin in Vincristine Resistant B-Cell Acute Lymphoblastic Leukemia.
Piktel D; Moore JC; Nesbit S; Sprowls SA; Craig MD; Rellick SL; Nair RR; Meadows E; Hollander JM; Geldenhuys WJ; Martin KH; Gibson LF
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765664
[TBL] [Abstract][Full Text] [Related]
36. Migration of acute lymphoblastic leukemia cells into human bone marrow stroma.
Makrynikola V; Bianchi A; Bradstock K; Gottlieb D; Hewson J
Leukemia; 1994 Oct; 8(10):1734-43. PubMed ID: 7523799
[TBL] [Abstract][Full Text] [Related]
37. Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia.
Boos J; Hohenlöchter B; Schulze-Westhoff P; Schiller M; Zimmermann M; Creutzig U; Ritter J; Jurgens H
Med Pediatr Oncol; 1996 Jun; 26(6):397-404. PubMed ID: 8614376
[TBL] [Abstract][Full Text] [Related]
38. Enhanced autophagy in cytarabine arabinoside-resistant U937 leukemia cells and its potential as a target for overcoming resistance.
Cheong JW; Kim Y; Eom JI; Jeung HK; Min YH
Mol Med Rep; 2016 Apr; 13(4):3433-40. PubMed ID: 26935591
[TBL] [Abstract][Full Text] [Related]
39. ERK/Drp1-dependent mitochondrial fission is involved in the MSC-induced drug resistance of T-cell acute lymphoblastic leukemia cells.
Cai J; Wang J; Huang Y; Wu H; Xia T; Xiao J; Chen X; Li H; Qiu Y; Wang Y; Wang T; Xia H; Zhang Q; Xiang AP
Cell Death Dis; 2016 Nov; 7(11):e2459. PubMed ID: 27831567
[TBL] [Abstract][Full Text] [Related]
40. The combination regimen of idarubicin and taxotere is effective against human drug-resistant leukemic cell lines.
Majlessipour F; Avramis IA; Kwock R; Weinberg KI; Avrami VI
Anticancer Res; 2002; 22(3):1361-8. PubMed ID: 12168812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
